报价延迟最少15分钟:2025/09/17 10:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.73 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.77/-0.25
|
|
企业价值
1.86B
|
| 资产负债 |
|
每股账面净值
9.35
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
465.31M
|
|
每股收益
7.66
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/17 10:06 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct salesforce and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. |
